このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Spero Therapeutics 将来の成長

Future 基準チェック /56

Spero Therapeuticsは、20.3%と22.6%でそれぞれ年率20.3%で利益と収益が成長すると予測される一方、EPSはgrowで15.4%年率。

主要情報

20.3%

収益成長率

15.4%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	22.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	06 Aug 2024

今後の成長に関する最新情報

Recent updates

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Jul 15

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why

Aug 11

業績と収益の成長予測

NasdaqGS:SPRO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	19	-90	-89	-88	2
12/31/2025	19	-103	N/A	-98	3
12/31/2024	26	-87	N/A	-57	3
6/30/2024	118	17	-14	-14	N/A
3/31/2024	111	23	-14	-14	N/A
12/31/2023	104	23	-33	-33	N/A
9/30/2023	78	-2	29	29	N/A
6/30/2023	54	-10	12	12	N/A
3/31/2023	54	-27	8	8	N/A
12/31/2022	54	-46	-8	-8	N/A
9/30/2022	9	-102	-80	-80	N/A
6/30/2022	10	-113	-84	-84	N/A
3/31/2022	13	-103	-77	-77	N/A
12/31/2021	18	-90	-64	-64	N/A
9/30/2021	17	-79	-53	-53	N/A
6/30/2021	18	-76	-70	-70	N/A
3/31/2021	15	-74	-78	-78	N/A
12/31/2020	9	-79	-86	-86	N/A
9/30/2020	11	-85	-87	-87	N/A
6/30/2020	12	-84	-75	-75	N/A
3/31/2020	12	-80	-63	-62	N/A
12/31/2019	18	-61	-50	-50	N/A
9/30/2019	16	-47	-49	-46	N/A
6/30/2019	12	-39	-45	-42	N/A
3/31/2019	11	-36	-41	-39	N/A
12/31/2018	4	-42	-42	-40	N/A
9/30/2018	3	-46	-39	-39	N/A
6/30/2018	3	-47	-44	-44	N/A
3/31/2018	3	-50	N/A	-44	N/A
12/31/2017	2	-46	N/A	-39	N/A
9/30/2017	1	-40	N/A	-36	N/A
6/30/2017	1	-35	N/A	-32	N/A
3/31/2017	0	-30	N/A	-29	N/A
12/31/2016	0	-30	N/A	-29	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SPROの予測収益成長率 (年間20.3% ) は貯蓄率 ( 2.5% ) を上回っています。

収益対市場: SPROの収益 ( 20.3% ) はUS市場 ( 14.9% ) よりも速いペースで成長すると予測されています。

高成長収益: SPROの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: SPROの収益 ( 22.6% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: SPROの収益 ( 22.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SPROの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Spero Therapeutics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 46%

Consensus EPS estimates upgraded to US$1.09 loss

Consensus revenue estimates fall by 50%

Consensus EPS estimates fall by 24%

Forecast to breakeven in 2026

Consensus revenue estimates increase by 21%, EPS downgraded

Recent updates

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 46%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Consensus EPS estimates upgraded to US$1.09 loss

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 50%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Investor sentiment improves as stock rises 15%

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates fall by 24%

Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New minor risk - Profitability

President notifies of intention to sell stock

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 21%, EPS downgraded

Price target increased by 18% to US$7.50

Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Consensus estimates of losses per share improve by 10%

Chief Medical Officer recently sold US$50k worth of stock

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Consensus estimates of losses per share improve by 38%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates increase by 35%

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Consensus revenue estimates fall by 36%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 53%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Consensus revenue estimates increase by 183%

Insufficient new directors

Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc

Spero Therapeutics to Present Data at IDWeek 2022

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc

Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer

Spero Therapeutics appoints Kamal Hamed MD CMO

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Consensus revenue estimates increase by 69%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Spero Therapeutics, Inc., Annual General Meeting, Sep 15, 2022

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of A Class Action Lawsuit

Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Its New Drug Application

Pomerantz Law Firm Announces the Filing of Class Action Lawsuit Against Spero Therapeutics, Inc

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind